# Trial of PDE4 Inhibition With Roflumilast (ARQ-154) Foam 0.3% for the Management of Seborrheic Dermatitis (STRATUM)

> **NCT04973228** · PHASE3 · COMPLETED · sponsor: **Arcutis Biotherapeutics, Inc.** · enrollment: 457 (actual)

## Conditions studied

- Seborrheic Dermatitis

## Interventions

- **DRUG:** Roflumilast Foam
- **DRUG:** Vehicle Foam

## Key facts

- **NCT ID:** NCT04973228
- **Lead sponsor:** Arcutis Biotherapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-07-08
- **Primary completion:** 2022-04-06
- **Final completion:** 2022-04-06
- **Target enrollment:** 457 (ACTUAL)
- **Last updated:** 2024-03-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04973228

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04973228, "Trial of PDE4 Inhibition With Roflumilast (ARQ-154) Foam 0.3% for the Management of Seborrheic Dermatitis (STRATUM)". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT04973228. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*